Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Gilead Sciences, Inc. (NASD: GILD), where a total volume of 43,947 contracts has been traded thus far today, a contract volume...
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) announced the
initiation of a Phase 2 clinical trial with the company's glucagon receptor
antagonist LGD-6972 for the treatment of type 2 diabetes mellitus. The
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Ligand Pharmaceuticals (LGND):